类风湿关节炎治疗反应可由微生物组预测:一项英国未使用改善病情抗风湿药患者的大型观察性研究
该多中心纵向观察性研究对未使用改善病情抗风湿药(DMARD)的新诊断类风湿关节炎(RA)患者进行粪便和唾液微生物组检测,基线144例、6周117例、12周95例,共365份粪便和365份唾液样本行鸟枪法测序。结果显示26种粪便微生物在达到最小临床重要改善的患者中减少,普雷沃菌属和链球菌属分别在DMARD治疗6周和12周后下降最明显,基线微生物组可预示未来治疗反应。
要点
- 在达到最小临床重要改善的RA患者中,26种粪便微生物减少。
- 普雷沃菌属在DMARD治疗6周后下降最明显,链球菌属在12周后下降最明显。
- 未用药RA患者的基线微生物组可预示未来对DMARD的治疗反应。
核心结论
- DMARDs似乎可使紊乱的微生物组恢复至真细菌状态。
- 微生物组状态可用于预测患者对DMARD治疗反应的可能性。
研究设计与样本
- 多中心、纵向、观察性研究,纳入未使用DMARD的新诊断RA患者,在DMARD治疗开始时收集粪便和唾液微生物组。
- 基线(n=144)为未用药患者,治疗6周(n=117)和12周(n=95)随访;共采集365份粪便和365份唾液样本行鸟枪法测序,各时间点收集疾病活动度指标并确定最小临床重要改善。
主要发现
- 共有26种粪便微生物在达到最小临床重要改善的患者中减少。
- 普雷沃菌属(Prevotella spp.)和链球菌属(Streptococcus spp.)分别是DMARD治疗6周和12周后下降的主要菌属。
- 未用药患者的基线微生物组可预示未来治疗反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Disease-modifying antirheumatic drugs (DMARDs) are a first-line treatment in rheumatoid arthritis (RA). Treatment response to DMARDs is patient-specific, dose efficacy is difficult to predict and long-term results are variable. The gut microbiota are known to play a pivotal role in prodromal and early-disease RA, manifested by Prevotella spp. enrichment. The clinical response to therapy may be mediated by microbiota, and large-scale studies assessing the microbiome are few. This study assessed whether microbiome signals were associated with, and predictive of, patient response to DMARD treatment. Accurate early identification of those who will respond poorly to DMARD therapy would allow selection of alternative treatment (e.g. biologic therapy) and potentially improve patient outcome. METHODS: A multicentre, longitudinal, observational study of stool- and saliva microbiome was performed in DMARD-naive, newly diagnosed RA patients during introduction of DMARD treatment. Clinical data and samples were collected at baseline (n = 144) in DMARD-naive patients and at six weeks (n = 117) and 12 weeks (n = 95) into DMARD therapy. Samples collected (n = 365 stool, n = 365 saliva) underwent shotgun sequencing. Disease activity measures were collected at each timepoint and minimal clinically important improvement determined. RESULTS: In total, 26 stool microbes were found to decrease in those manifesting a minimal clinically important improvement. Prevotella spp. and Streptococcus spp. were the predominant taxa to decline following six weeks and 12 weeks of DMARDs, respectively. Furthermore, baseline microbiota of DMARD-naive patients were indicative of future response. CONCLUSION: DMARDs appear to restore a perturbed microbiome to a eubiotic state. Moreover, microbiome status can be used to predict likelihood of patient response to DMARD.
引用
- Danckert NP, Freidin MB, Granville Smith I, et al. Treatment response in rheumatoid arthritis is predicted by the microbiome: a large observational study in UK DMARD-naive patients. Rheumatology (Oxford). 2024. PMID: 38291926. doi:10.1093/rheumatology/keae045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。